drugset / Trial / NCT02149420

PD of VAY736 in Patients With Primary Sjögren's Syndrome

NCT02149420

Phase 2 Completed 27 enrolled Novartis Pharmaceuticals
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study was designed to evaluate the safety, tolerability, pharmacokinetics and therapeutic efficacy of a single intravenous infusion of VAY7346 monoclonal antibody in pSS patients

Timeline

Start
2014-05-23
Primary completion
2018-02-07
Completion
2018-02-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Ianalumab Monoclonal antibody 3 mg/kg Intravenous
Subject Ianalumab Monoclonal antibody 10 mg/kg Intravenous

Indications